General Announcement::Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
17-Sep-2019 11:25:02
Status
New
Announcement Sub Title
Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate
Announcement Reference
SG190917OTHRGBG3
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
17/09/2019 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark Receives Orphan Drug Designation for GBR 1342, a Bispecific Antibody Candidate Under Evaluation for the Treatment of Multiple Myeloma

Attachments

PR_SGX_17092019.pdf
Total size =189K